Choroideremia Market Trends and Growth Analysis, Novel Therapies, Emerging Technologies, Leading Companies, and Epidemiology Forecast

Choroideremia Market Trends and Growth Analysis, Novel Therapies, Emerging Technologies, Leading Companies, and Epidemiology Forecast

“Delveinsight Business Research LLP”
DelveInsight’s “Choroideremia Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Choroideremia Market Size and Share in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Choroideremia is a condition categorized by progressive vision loss which usually affects males. The first and foremost symptom of this condition is an impairment of night vision, also known as night blindness, which can occur in early childhood, as well as, tunnel vision (a narrowing field of vision), and visual activity (decrease in the ability to see details). Other names for this condition are: Collapse Section, choroidal sclerosis progressive tape choroidal dystrophy, and TCD

Choroideremia is inherited in an X-linked recessive pattern. The CHM gene is located on the X chromosome, which is one of the two sex chromosomes. In males (who have only one X chromosome), one altered copy of the gene in each cell is sufficient to cause the condition.

Get FREE sample copy at:

The Choroideremia Market Research Report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted Choroideremia market Size from 2017 to 2030 segmented by seven major markets. 

The report provides a detailed current Choroideremia treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Choroideremia Market

Choroideremia Market Key Facts

  • According to the National Organization for Rare Diseases (NORD), choroideremia affects primarily males. However, a small number of females develop the disorder as a result of a genetic process that inactivates the normal gene and leaves only the dysfunctional gene active.

  • According to the study by Pequignot et al. (2014), choroideremia represents 2% of retinal dystrophies and is characterized by night blindness in childhood leading to blindness by 50 years of age.

  • The prevalence of choroideremia is estimated to be 1 in 50,000–100,000 people. However, it is likely that this condition is underdiagnosed because of its similarities to other eye disorders (National Institute of Health (NIH)).

  • According to the NIH, this condition is underdiagnosed because of its similarities to other eye disorders. Choroideremia is thought to account for approximately 4% of all blindness.

Key Benefits of Choroideremia Market Report

  • The market report provides an in-depth analysis of Choroideremia Market Size, Share, Trend, and Epidemiology Forecast till 2030 in the seven major markets (i.e. the United States, EU5 (Germany, Italy, Spain, France, and the UK) and Japan.

  • The report will help in developing business strategies by understanding the Choroideremia Market Trends, recent developments, key players, and future market competition that will shape and drive the market growth in the upcoming years.

  • The market report covers the Choroideremia current treatment practices, emerging drugs, market share of the individual therapies in the seven major markets.

  • The report provides a detailed assessment of the Choroideremia market in terms of market drivers & barriers, unmet needs, market opportunities, patient population, detailed comparative analysis of pipeline products including clinical and non-clinical stage products, and other factors. 

Choroideremia Market 

Choroideremia Market Size is expected to increase during the forecast period owing to the prevalence of Choroideremia, along with the expected launch of emerging therapies such as Spark Therapeutics’ SPK-7001, Biogen‘s BIIB111 (AAV2-REP1), and 4D Molecular Therapeutics’ 4D-110. The pipeline for Choroideremia brings a positive ray of hope for a better treatment pattern in the market in the upcoming years.

The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Choroideremia market size and share by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.

The report gives a thorough detail of the Choroideremia market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Request for Sample @ Choroideremia Therapeutics Market Assessment

Choroideremia Epidemiology

The epidemiology section covers insights about the historical and current Choroideremia patient pool and forecasted trends for every seven major countries from 2017 to 2030. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Choroideremia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Choroideremia market or expected to get launched in the market during the study period. The analysis covers Choroideremia market uptake by drugs; patient uptake by therapies; and sales of each drug.   

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Choroideremia Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.

Some of the key companies in the Choroideremia Market include:

  • Biogen

  • Spark Therapeutics

  • 4D Molecular Therapeutics (4DMT)

And many others. 

Choroideremia Therapies covered in the report include:

  • SPK-7001 (AAV2-hCHM)

  • BIIB111 (AAV2-REP1)

  • 4D-110

And many more. 

The launch of these emerging therapies is expected to significantly impact the treatment scenario of Choroideremia in the coming years.

 Table of Content

1. Key Insights

2. Executive Summary 

3. Choroideremia Competitive Intelligence Analysis

4. Choroideremia Market Overview at a Glance

5. Choroideremia Disease Background and Overview

6. Choroideremia Patient Journey

7. Choroideremia Epidemiology and Patient Population

8. Choroideremia Treatment Algorithm, Current Treatment, and Medical Practices

9. Choroideremia Unmet Needs

10. Key Endpoints of Choroideremia Treatment

11. Choroideremia Marketed Products

12. Choroideremia Emerging Therapies

13. Choroideremia Seven Major Market Analysis

14. Attribute Analysis

15. Choroideremia Market Outlook (7 major markets)

16. Choroideremia Access and Reimbursement Overview

17. KOL Views on the Choroideremia Market.

18. Choroideremia Market Drivers

19. Choroideremia Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The table of contents is not exhaustive; the final content may vary. 

Get FREE sample copy at:

Latest Reports By DelveInsight

Choroideremia Pipeline Insights

Choroideremia Pipeline Insights, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Choroideremia market.

Electroencephelographs (EEG) Pipeline Insight

DelveInsight’s, “Electroencephelographs (EEG) Pipeline Insight and Competitive Landscape, 2020,” report provides comprehensive insights about 20+ companies and 20+ pipeline devices in Electroencephelographs pipeline landscape. The report provides a detailed study of the emerging Electroencephelographs devices along with competitive landscape to help better understand the emerging Electroencephelographs devices and also covers the present clinical development scenario and growth prospects across Electroencephelographs (EEG) market.

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States